![Takashi Toraishi Profile Photo](https://rakuten-med.com/us/wp-content/uploads/sites/6/2023/02/TAKASHI-TORAISHI068fx-1.jpg)
Takashi Toraishi
Co-Chief Executive Officer (Co-CEO) and President
Takashi “Tora” Toraishi is the Co-CEO, President and Board of Director of Rakuten Medical Inc. He has been part of Rakuten Medical (formerly Aspyrian Therapeutics Inc.) since 2017. Under his leadership, ASP-1929, the first asset based on the Alluminox™ platform, was successfully approved in September 2020 by the Japanese Ministry of Health, Labour, and Welfare under the Sakigake Designation System and the Conditional Early Approval System, and was commercialized in Japan in January 2021.
Previously, Tora was an executive officer of new service development company at Rakuten Group, Inc., where he spearheaded company-wide innovation initiatives and multiple joint ventures. For nine years, Tora worked with McKinsey & Company, Asia, leading the industrial practice as a Partner. He started his career as an assistant professor of engineering at the University of Tokyo and led the nuclear chemistry division of the Japan Atomic Energy Agency. Tora received his B.A. in Engineering and his Master’s in Engineering at the University of Tokyo, his Licentiate of Engineering, Inorganic Chemistry at the Royal Institute of Technology at Stockholm, as well as his Ph.D. in Nuclear Chemistry from the University of Tokyo.